Case Study: GLP-1 agonists in type 2 diabetes

Rybelsus (semaglutide) is a daily oral GLP-1 agonist for Type 2 diabetes that has A1C lowering as strong as injected Victoza (liraglutide) 1.8mg and somewhat better weight loss (-4.4kg versus -3.1kg to week 26), with similar gastrointestinal side effects. For proper oral absorption, it must be taken at least 30 minutes before the first food, beverage, or other oral medications of the day.